Biocon Limited
 

11/01/2017 6:40PM

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan’s biologics license application (BLA) for ...

27/12/2016 12:52PM

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the results of the HERITAGE study have been published in the Journal of the American Medical Association (JAMA). Study ...

12/11/2016 10:00AM

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India

Biocon Ltd., Asia's premier biopharmaceuticals enterprise and the largest Indian insulins company, has collaborated with healthcare specialists for a month long patient centric support program to enable nationwide ...

08/11/2016 7:04PM

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Potential to be First Submission of a Proposed Biosimilar Trastuzumab in the U.S. Marks First U.S. Regulatory Submission through the Mylan/Biocon Collaboration and Important Step in Expanding Access to Biosimilars ...

03/11/2016 7:12PM

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine; Accepted for Review by European Medicines Agency

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Application (MAA) for ...

28/10/2016 6:42PM

Biocon Ranked Among Global Top Ten Biotech Employers

Biocon moves up to No. 9 from No. 13 last year    Biocon Ltd. (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that it has been ranked among the ...

20/10/2016 8:30PM Document

Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today its consolidated financial results for the second quarter ended on September 30th, 2016. Commenting on the ...

25/08/2016 5:27PM

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Application (MAA) for ...

First<1234>Last